Rhythm Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RYTM | MBX | CRNX | ARWR | CORT | 688759.SS | |
|---|---|---|---|---|---|---|
| Market cap | 7.67B | 2.53B | — | 8.71B | 8.56B | 7.56B |
| P/E (TTM) | — | — | — | — | 59.6 | — |
| Forward P/E | -170.1 | -13.2 | — | -12.4 | 18.8 | — |
| Price/book | 87.2 | 6.1 | — | 18.7 | 10.4 | 4.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −13.10% | +143.90% | — | +47.68% | +6.89% | −52.52% |
| Today | +28.04% | −4.58% | 0.00% | +3.56% | −3.31% | +4.42% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RYTM news ›Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.50 According to Brokerages
Posted by Defense World Staff on Oct 25th, 2026 Get Our Latest Analysis on Rhythm Pharmaceuticals Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of…
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired…
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ... Rhythm Pharmaceuticals Announces…
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired...
IMCIVREE initially received marketing authorization in the UK in 2021 for the treatment of obesity and control of hunger in patients with POMC, PCSK1 or LEPR deficiency and in 2022 for patients with Bardet-Biedl syndrome (BBS). In 2024,…
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Gets Price Target Cut from JPMorgan Chase & Co.
Posted by Danessa Lincoln on Oct 18th, 2026 Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price target trimmed by JPMorgan Chase & Co. from $146.00 to $145.00 in a report published on Thursday,Benzinga reports. The brokerage…
JPMORGAN CHASE & CO Adds Rhythm Pharmaceuticals Inc (RYTM) -- Shares Look 33% Undervalued on GF Value
GuruFocus JPMORGAN CHASE & CO Adds Rhythm Pharmaceuticals Inc (RYTM) -- Shares Look 33% Undervalued on GF Value On Sept. 30, 2026, JPMORGAN CHASE & CO disclosed an addition to its position in Rhyth
Rhythm Pharmaceuticals: JPMorgan reports 5.1% stake
JPMorgan reports 3.56 million shares in Rhythm Pharmaceuticals (RYTM), exceeding the 5% threshold. Stock Titan - [SCHEDULE 13G] RHYTHM PHARMACEUTICALS, INC. Passive Investment Disclosure (>5%) Rhythm Pharmaceuticals: JPMorgan reports 5.1%…
Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Acquired Hypothalamic Obesity Following MHLW Approval
IMCIVREE is approved to treat acquired hypothalamic obesity in Japan, marking it as the first therapy for this condition. IMCIVREE was commercially launched in Japan on October 13, 2026, after receiving MHLW approval. IMCIVREE is an MC4R…
Nomad Foods Limited (NYSE:NOMD) Stock Has Average Price Target of $13.50
Read Our Latest Research Report on Nomad Foods The company also recently declared a quarterly dividend, which was paid on Thursday, August 27th. Shareholders of record on Tuesday, August 11th were issued a $0.17 dividend. The ex-dividend…
JPMorgan trims Rhythm Pharmaceuticals target, adds to Analyst Focus List
JPMorgan analyst Priyanka Grover lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $145 from $146 and keeps an Overweight rati... JPMorgan trims Rhythm Pharmaceuticals target, adds to Analyst Focus List JPMorgan analyst…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- markets.businessinsider.com7
- themarketsdaily.com2
- defenseworld.net1
- gurufocus.com1
- marketbeat.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.